- About us
- About Vaccines
- Media centre
- EU initiatives
Europe is at the heart of global vaccine research and production. Most of the activities of the major innovative Vaccines Europe members research based-companies are based in the region.
The Early Career Research Prize in Vaccinology R&D is awarded by the International Union of Immunological Societies (IUIS) with the contribution of Vaccines Europe. The objective is to promote and foster a younger generation of scientists in the early stages of their career.
The prize rewards significant achievements in Vaccine R&D, including the discovery of new vaccine antigens, new vaccines design, understanding the basics of the immune response, new technologies that will improve the future of vaccines and vaccination and that are supported by proof-of-concept data (preclinical and clinical).
Vaccines Europe is pleased to announce that Pascale Mauran, Vice-President, IDM Vaccines Commercial Development at Pfizer, has been officially appointed as the new Vaccines Europe President. Pascale Mauran has been representing Pfizer on the Vaccines Europe Board for four years now, out of which one and half year as Vaccines Europe Vice-President. She brings solid experience and expertise on vaccines to help drive the development of the Vaccines Europe objectives. Pascale Mauran’s appointment as President will start immediately and will run for the next two years.
Pascale Mauran stated: “I am delighted to take the responsibility of President of Vaccines Europe and continue to drive Vaccines Europe strategy and vision in this significant momentum for vaccination in Europe with the EU Joint Action on Vaccination and all other important EU initiatives underway”.
Vaccines Europe expresses its gratitude to its former President Andrea Rappagliosi, for his strong leadership dedicated to Vaccines Europe over the past 5 years.
For more information, please contact:
Magdalena R. de Azero, Executive Director, Vaccines Europe
Vaccines Europe welcomes the European Commission initiative to launch the EU Joint Action on Vaccination. This EU Joint Action represents a unique opportunity to address common challenges faced by the EU Member States as highlighted in the Council Conclusions on vaccinations as an effective tool in public health, in December 2014. This becomes even more relevant against a background of increasing vaccine-preventable disease outbreaks leading to avoidable death and disability, the increase of antimicrobial resistance and the ageing of the population.
The vaccine industry shares the commitment of the entire public health community to protect European citizens of all ages against infectious diseases. Vaccines Europe is committed to working with stakeholders to ensure a reliable supply of safe, effective and innovative vaccines in Europe and worldwide. Vaccines Europe has identified a number of key areas, which could significantly strengthen vaccination in Europe and facilitate the achievements of European Immunisation goals.
Access and download our paper here.